| Abstract |
Menarini is developing the anthracycline aminodisaccharide MEN-10755 for the potential treatment of solid tumors. Six phase II trials began in 2000 to verify the therapeutic activity of the drug in a variety of tumors, including sarcoma and those of the ovary, breast, prostate and lung. |
| Authors | Kellie Jones |
| Journal | Current opinion in investigational drugs (London, England : 2000)
(Curr Opin Investig Drugs)
Vol. 4
Issue 12
Pg. 1473-8
(Dec 2003)
ISSN: 1472-4472 [Print] England |
| PMID | 14763135
(Publication Type: Journal Article, Review)
|
| Chemical References |
- Disaccharides
- Drugs, Investigational
- Enzyme Inhibitors
- Topoisomerase II Inhibitors
- Doxorubicin
- DNA Topoisomerases, Type II
- sabarubicin
|
| Topics |
- Animals
- Clinical Trials as Topic
(statistics & numerical data)
- DNA Topoisomerases, Type II
(metabolism)
- Disaccharides
(adverse effects, chemistry, pharmacology, therapeutic use)
- Doxorubicin
(adverse effects, analogs & derivatives, chemistry, pharmacology, therapeutic use)
- Drugs, Investigational
(adverse effects, chemistry, pharmacology, therapeutic use)
- Enzyme Inhibitors
(chemistry, pharmacology, therapeutic use)
- Humans
- Neoplasms
(drug therapy, enzymology)
- Technology, Pharmaceutical
(methods)
- Topoisomerase II Inhibitors
|
